Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-11, Vol.176, p.207-217
Hauptverfasser:	Khattak, Muhammad A., Luke, Jason J., Long, Georgina V., Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Robert, Caroline, Grob, Jean-Jacques, de la Cruz Merino, Luis, Del Vecchio, Michele, Spagnolo, Francesco, Mackiewicz, Jacek, Chiarion-Sileni, Vanna, Carlino, Matteo S., Mohr, Peter, De Galitiis, Federica, Ross, Merrick I., Eroglu, Zeynep, Chen, Ke, Jiang, Ruixuan, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Eggermont, Alexander M.M., Kirkwood, John M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant Adjuvants, Immunologic - therapeutic use Global health Health risks Humans Immunotherapy Melanoma Melanoma - drug therapy Melanoma - surgery Melanoma, Cutaneous Malignant Monoclonal antibodies Neoplasm Recurrence, Local Patient-reported outcomes Pembrolizumab Placebos Public health Quality of Life Safety management Targeted cancer therapy Toxic diseases Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients ≥12 to
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2022.08.004